Salarius Pharmaceuticals

Executive Summary

Salarius Pharmaceuticals, operating as Decoy Therapeutics, is a preclinical biotechnology company pioneering Designable Multi-Antivirals (DMAVs) based on its IMP³ACT platform. The platform integrates AI-enabled design with rapid peptide-conjugate synthesis to target conserved viral mechanisms, enabling broad-spectrum antiviral activity. The company's lead programs focus on self-administered nasal sprays for respiratory viruses including coronaviruses, influenza, and RSV, addressing the 'tripledemic' threat. Despite being in early development with limited public data, the platform's differentiated approach and potential for broad-spectrum efficacy position it uniquely in the antiviral space. The company is privately held with a modest valuation of ~$3.1M, reflecting its preclinical stage.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data for lead DMAV candidate40% success
• TBDIND-enabling studies initiation or completion30% success
• TBDStrategic partnership or licensing deal for IMP³ACT platform25% success